Sigrid Therapeutics has entered into an agreement with Cencora aimed at accelerating the commercialization of its SiPore technology.

SiPore21 is currently undergoing SHINE clinical trials as an innovative medical device designed for sustained blood sugar and weight control. Administered orally, SiPore21 utilizes a mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods, describes the company. In addition to obesity and diabetes, Sigrid is also actively pursuing SiPore applications in other markets, including food supplements, veterinary, and oral health, it states.

Ready to accelerate commercialization

“With SiPore’s clinical development for obesity and blood sugar control advancing at a rapid pace and funding secured in our recent over-subscribed round, we are ready to accelerate commercialization,” says Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics. “After an extensive search, we have identified Cencora as a partner who understands fully our expectations and will be able to help us fulfil our ambition to introduce one of the most important innovations in obesity and diabetes treatment.”

Cencora will provide a variety of services, including strategy consulting, regulatory consulting, and market access support, to strategize the market introduction of the SiPore technology, pending regulatory approval.

“We’re thrilled to support Sigrid Therapeutics’ pre-commercial launch preparations as the company moves toward a potential launch in the United States and Europe,” says Willis Chandler, President of Global Pharma Services at Cencora.

Photo of Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics